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Book Reviews
Taoxifen: Moecclr Bass of use in Cancer Treatment and
Prevention
H Wiseman, John Wiley: Chichester, 1994, 209 pp. £29.95.
ISBN 0 471 94316 9.
This book provides a timely overview of this important anti-
cancer drug. An introductory chapter includes useful
synopses of each of the following chapters. The next four
chapters deal with aspects of the chemistry, pharmacology,
metabolism and clinical use of tamoxifen and its actions on
the oestrogen receptor. Many of these individual topics have
been extensively reviewed elsewhere, but it is useful to have
them all brought together in one volume. Where appropriate,
the author has often prefaced discussion ofeach topic with a
brief general introduction to the biological background. For
example the chapter on Metabolism and Toxicology (Chapter
3) begins with a useful summary of the CYP nomenclature
used for classifying cytochrome P450 enzymes. The author
covers most of the major areas of interest and current
controversy. The references at the end ofeach chapter though
not comprehensive, are sufficient to allow the reader to gain
entry into the literature of a particular field. These are
commendably up to date, some predating publication of the
book by only a month or two. An example (p. 27) is a
reference to a recent hypothesis that proposes how tamoxifen
produces liver DNA adducts.
More than half the book is concerned with apparently
oestrogen-independent actions oftamoxifen, the later chapters
reflecting the author's personal research interests. This is
nevertheless welcome, as it provides a different emphasis from
most reviews on this drug. The first of these later chapters
describes how tamoxifen modulates certain oncogenes and
growth factors. Again there is a simple introduction to
oncogenes and the relevant growth factor accompanied by
clear diagrams illustrating their functions. This chapter also
includes a discussion of mechanisms of resistance. Inhibition
ofenzymes is the main subject ofthe following chapter. These
include enzymes in cell signalling pathways, such as protein
kinase C (PKC), and calmodulin-dependent enzymes. There
follows a discussion of the role of the anti-oestrogen binding
site (AEBS). A minor criticism here is that the discussion of
the structural requirements for ligand binding refers to the
work ofVan den Koedijk et al. on the rat AEBS. Their later,
potentially more relevant, study on the human AEBS shows a
different structure-activity relationship.
A discussion of the effect of tamoxifen and 4-hydroxy-
tamoxifen on cholesterol synthesis forms a useful prelude to a
following chapter on the antioxidant action of tamoxifen.
The first 17 pages of this chapter are a general description of
cell membrane structure and function. However, this lengthy
introduction is a necessary background to the discussion that
follows. In this, the basis thesis is that tamoxifen protects the
cell membrane against lipid peroxidation by decreasing
membrane fluidity. A variety of beneficial consequences
proposed to result from this action include inhibition of
metastasis, reversal of the multidrug resistance phenotype
and cardio-protection.
The penultimate chapter describes the actions oftamoxifen
on the yeast Saccharomyces cerevisiae. Analogies with
mammalian control mechanisms justify the use of the yeast
model. These include similarities in Ras- and PKC-mediated
pathways, and in functions of calmodulin. Moreover, the
model may help to validate tamoxifen as a candidate drug for
use in fungal infections caused by Candida.
The brief concluding chapter compares tamoxifen with
some of its major competitors, to which the book also refers
earlier. This last chapter also mentions an approach to the
design of a compound, structurally similar to tamoxifen,
which could treat prostatic cancer.
In attempting to cover all aspects of tamoxifen's actions,
the treatment of some topics has been at times uncritical of
interpretations found in the literature. Occasionally this has
led to factual errors and contradictory statements. For
example, it is probably not true that ovarian cancer cells can
metabolise tamoxifen to 4-hydroxytamoxifen (p. 22). Induc-
tion of TGF f (p. 63) is a more likely basis for the anti-
carcinogenic effect oftamoxifen than suppression ofhydrogen
peroxide production by neutrophils (p. 147). 4-Hydroxyta-
moxifen is a potent inhibitor ofthe growth ofMCF-7 cells (p.
22). This is incompatible with the later statement (p. 165) that
it does not inhibit yeast cell growth 'probably because it is a
polar compound and is unable to enter the yeast cell'. Of the
tamoxifen analogues toremifene and droloxifen (p. 27), only
the latter has a shorter half-life than the parent drug.
Moreover, this is not necessarily advantageous as the
literature claims (p. 197). Compared with tamoxifen, it will
lead to a lower exposure of the drug for a given dose.
However, these are minor criticisms. Generally, the broad
coverage is beneficial, serving to stimulate though this suggests
fruitful avenues for further research.
This useful and highly readable volume should be on the
bookshelves foreveryone engagingin research on tamoxifen. It
also contains much to interest the general reader. Many
research areas covered as fast moving and facts and
interpretations quickly date. I hope, therefore, that the author
may in due course find time to produce a revised version.
M Jarman
Drug and Hormol Resstanc in Breat Cancer: Celabr and
Molecudr Mecdia_m
Edited by RB Dickson and ME Lippman, Ellis Horwood:
Hemel Hempstead, 1995, 440 pp. £112.50. ISBN 0-13-224858-
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This is generally an excellent book giving a thorough
treatment to an area of major clinical importance. The
editors themselves are well known as excellent researchers in
this field but they did not in fact contribute substantially to
the writing. They have, however, been able to attract a first
class array of writers to cover the subject comprehensively.
The book is divided into four parts with parts 2 and 3
making up about two-thirds of the book:
1. Clinical Resistance
2. Antihormonal Drugs: mechanism of action and resis-
tance
3. Chemotherapeutic Drugs: mechanisms of resistance
4. Chemohormonal Interactions.
In Part 1 Tripathy and Henderson contribute an excellent
chapter discussing the general approach for deriving
mechanistic data from clinical trials while emphasising the
danger of simple intrapolation and extrapolation. A chapter
by Gusterson on the changing role of the pathologist in
predicting tumour behaviour and response to treatment
might not be expected in this book but nonetheless contains
worthwhile data.
Throughout the clinical resistance section and Part 2 there
is substantial repetition. For example, the data on the
importance of c-erb-2 as an indicative marker of response/
resistance to adjuvant chemotherapy must be mentioned in
two-thirds of the chapters. It is likely, however, that theBook
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majority of readers will be looking at individual chapters or
using this as a reference text, thus repetition is inevitable to
ensure comprehensiveness in the individual chapters. The
chapter by Petros and Peters on dose intensity to overcome
drug resistance deals with resistance more by implication
than by direct reference to resistance data, and avoids dealing
with the controversies. The chapters on molcular mechan-
isms of anti-oestrogen resistance and tamoxifen metabolism
from the groups Jordon and Osborne unfortunately lack the
more recent data on non-isomerisable tamoxifen derivatives,
which is an important component of the current interpreta-
tion of data from this field. This illustrates a more general
point: throughout there are almost no references beyond
1992. The two chapters on progestins and anti-progestins
have few data on resistance to these compounds, but they
provide a useful summary of data from in vitro models.
Part 3, dealing with chemotherapeutic drugs, has
substantial overlap throughout some of the chapters on
multi-drug resistance and the importance of MDRI. The
chapter by Goldstein is in itself quite exhaustive, taking this
area from the molecular through to importance in clinical
trials. It goes outside of the breast cancer area dealing
substantially with areas where MDRl involvement is
apparently more important. Further chapters on non-
MDRl-associated resistance include the importance of extra
chromosomal DNA, which is somewhat speculative in
contrast to the chapter on fluoropyrimidine chemotherapy
which deals with quite well-known data. The chapter by
Harris and Carmichael gives a comprehensive discussion
specifically on topoisomerase inhibitors, as well as reflecting
on the relevance ofmultidrug resistance mechanisms to them.
Weisenthal provides a valuable discussion for those
interested in in vitro tests to predict breast cancer sensitivity
to these agents. This particular chapter is unusual in this
book in that the tables are poorly annotated and reduced in
value as a result of that.
The last two chapters on approaches to reversing multi-
drug resistance could have been excluded since they are
highly repetitive of other chapters in this section.
The three chapters on chemohormonal interactions deal
with separate issues: (i) the relationship between cell kinetics
and hormonal receptors and their utility for treatment
selection; (ii) hormonal synchronisation before chemother-
apy, reflecting that this has proven to be uniformly without
benefit; (iii) an extensive laboratory-orientated discussion of
the interactions of chemo- and hormonal therapy in cell
culture. It would have been valuable either within the context
of this last chapter or possibly by the inclusion of an extra
chapter to have given a further discussion of the interaction
of these drugs in vivo, particularly since the 'overview'
analysis of 1992 of adjuvant treatments in breast cancer
provided compelling indirect evidence on the additive effects
of these two approaches in the adjuvant setting.
Overall Ifoundittobehighlyreadableandvaluable, and the
wide interest ofsuch a text was emphasised to me by the large
number ofpeople that picked up the book while I wascarrying
it with me over a period of some weeks. Many of them
requested details in order that theycould purchase it. I for one,
will be guarding this book in my cabinet carefully since I am
sure that it is one ofthose which will walk very easily.
M Dowsett
Noo-Reproductive Actioi of Sex Steroids
Edited by GR Bock and JA Goode, John Wiley & Sons:
Chichester, 1995, 307pp. £49.95, ISBN 0 471 95513 2.
CIBA FOUNDATION SYMPOSIUM 191:
NON-REPRODUCTIVE ACTIONS OF SEX STEROIDS
The reports of the Ciba Foundation Symposia always make
interesting reading, dealing as they do with topics at the
leading edge of science or medicine, and bringing together
leading investigators in the area. This meeting, held in August
1994, is no exception. It turns the spotlight away from the
reproductive aspects ofthe sex steroids, which havejustifiably
attracted extensive exploration, and focuses it on the wider
role that these hormones play in a variety of other
physiological processes.
In the first paper, Miguel Beato reviews our knowledge of
how steroid hormones modulate the expression of a variety
of genes by binding to hormone-responsive elements of DNA
or interacting with various transcription factors to influence
signal transduction pathways. The interactions of hormone,
receptor and the several other factors involved are complex,
and an important mechanism may involve the hormone itself
changing the chromatin structure. Similarly, the concept of
antihormones occupying the receptor site, thereby preventing
hormone action, may be only one of several possible
mechanisms, and specific binding sites for antihormones
may also exist.
Etienne-Emile Baulieu points out that non-genomic
mechanisms of hormone action are also important. Effects
of membrane interaction and changes in membrane structure
have been noted, and the role of binding proteins influencing
intracellular machinry is still unclear. There are several
examples of progestagens influencing biochemical activity at
the membrane and also modulating calcium entry into cells.
Bruce McEwen discusses neural effects of steroids. Apart
from their well-known role in reproduction, they also affect
pain perception, cognitive function and mood. Oestradiol
induces choline acetyltransferase activity in the forebrain
and reduces synapse density. The mechanism is unclear, only
a few classical oestrogen receptors exist in pyramidal cells,
although the oestrogen receptor may perhaps be atypical.
Interestingly, hormone replacement therapy (HRT) has been
reported to ameliorate the symptoms of Alzheimer's disease.
Michael Schumacher discusses the role of sex steroids in
nerve repair. Progesterone is actively synthesised and
metabolised in brain tissue, and the hormone or its
metabolites may accelerate the repair of myelin sheaths
after injury.
Thereisalesserincidenceofcoronaryheartdiseaseinwomen
than in men. It is likely that oestradiol is a major factor, the
mechanism, in part, involving lipoprotein changes. Francis
Bayard's paperpoints out thatdirect effects on the blood vessel
wall should not be ruled out. The enzymes that synthesise and
metaboliseoestrogensarepresent onthevascularwall, andtheir
effects on cytokines, growth factors and vasoregulatory
molecules are probably involved in the pathogenesis of
arteriosclerosis. Following this theme, Marie Foegh presents
data on transplant arteriosclerosis, which is a major clinical
problem. Oestradiol profoundly influences the immune system
anditisnotablethatwomenaremoresusceptibletoautoimmune
diseases than men are. Oestrogens enhance the differentiation
and maturation oflymphocytes and diminish suppressor T-cell
function. Intransplantpatients, HRTisanunfavourablefactor.
However, in an animal modeL oestradiol inhibited myointimal
hyperplasia and prevented entry of macrophages, which is
probably the initiating factor. Thus, oestradiol has complex
effectsonthevascularsystem,stillnotwelldefinedorunderstood.
Madge Vickers reports that coronary heart disease is the
most common cause ofdeath in post-menopausal women and
that some protection is given by HRT. She describes a
proposed epidemiological study of users of HRT in the UK
and elsewhere in Europe, which would address many of the
unanswered questions, including the effect of HRT on
vascular disease. The problems with such a trial are
considerable (e.g. changing fashions in dose, type of steroid,
route of administration) but if the trial were postponed, no
answer would ever be forthcoming.
Torbjorn Backstrom considers the effects of oestrogen on
mooyd. Progestogens may increase depression, and progester-
one and some of its metabolites can cause anaesthesia.
Indeed, this observation has been used in clinical practice.
Oestrogens can alter sensory perception, locomotory activity